Chen Yunsheng, Zhang Zheng, Xin Yu, Zhou Rong, Jiang Kai, Sun Xiyang, He Dannong, Song Jie, Zhang Yixin
Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, 639 Zhizaoju Road, Shanghai 200011, P.R. China.
Department of Orthopedic, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Nanoscale. 2020 Jul 23;12(28):15435-15442. doi: 10.1039/d0nr03494k.
Photodynamic therapy (PDT) is a new therapeutic strategy for hypertrophic scars (HS), but it is limited by low drug utilization. Transdermal delivery based on nanoethosomes (ES) has attracted considerable attention as a potential clinical strategy in PDT treating HS. However, free ES are unsatisfactory due to their instability and non-targeting, which causes non-effective delivery and low drug utilization. Herein, 5-aminolevulinic acid (ALA)-loaded ES (ES-ALA) embedded in hyaluronic acid (HA) meshes (HA/ES-ALA), a novel synergistic transdermal delivery nanogel, are developed for enhancing PDT of HS. HA/ES-ALA has a unique structure and property to protect unilaminar ES-ALA with HA meshes and actively target hypertrophic scar fibroblasts (HSFs) with HA receptors. Both in vitro and in vivo experiments demonstrate that HA/ES-ALA has a remarkable transdermal delivery ability with penetrating channels and a membrane-fusion mechanism. Meanwhile, the synergistic delivery mechanism is visually characterized as three stages: synergistic penetration, targeting aggregation and transmembrane delivery. With the synergistic effect, HA/ES-ALA can realize a targeted transdermal delivery, and significantly improve ALA utilization and enhance PDT efficacy. The results demonstrate an effective transdermal delivery route to enhance therapy for HS as well as other skin diseases.
光动力疗法(PDT)是一种针对增生性瘢痕(HS)的新型治疗策略,但它受到药物利用率低的限制。基于纳米脂质体(ES)的透皮给药作为PDT治疗HS的一种潜在临床策略已引起广泛关注。然而,游离的ES由于其不稳定性和非靶向性而不尽人意,这导致给药无效和药物利用率低。在此,开发了一种新型的协同透皮给药纳米凝胶——嵌入透明质酸(HA)网中的负载5-氨基乙酰丙酸(ALA)的ES(ES-ALA,即HA/ES-ALA),用于增强HS的PDT效果。HA/ES-ALA具有独特的结构和性质,可通过HA网保护单层ES-ALA,并通过HA受体主动靶向增生性瘢痕成纤维细胞(HSF)。体外和体内实验均表明,HA/ES-ALA具有显著的透皮给药能力,其机制包括穿透通道和膜融合机制。同时,协同给药机制在视觉上表现为三个阶段:协同渗透、靶向聚集和跨膜递送。通过协同作用,HA/ES-ALA可以实现靶向透皮给药,并显著提高ALA的利用率,增强PDT疗效。结果证明了一种有效的透皮给药途径,可增强对HS以及其他皮肤病的治疗效果。